X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18150) 18150
Book Chapter (206) 206
Newspaper Article (58) 58
Newsletter (45) 45
Magazine Article (41) 41
Publication (8) 8
Dissertation (5) 5
Book / eBook (4) 4
Trade Publication Article (4) 4
Reference (3) 3
Conference Proceeding (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16508) 16508
science & technology (13635) 13635
life sciences & biomedicine (13334) 13334
male (8904) 8904
female (8168) 8168
platelet aggregation inhibitors - therapeutic use (8161) 8161
middle aged (6712) 6712
aged (6477) 6477
cardiovascular system & cardiology (6455) 6455
platelet aggregation inhibitors - adverse effects (6428) 6428
cardiac & cardiovascular systems (4745) 4745
treatment outcome (4511) 4511
ticlopidine - analogs & derivatives (4343) 4343
risk factors (4269) 4269
platelet aggregation inhibitors - administration & dosage (4246) 4246
abridged index medicus (3265) 3265
aspirin (2843) 2843
aspirin - therapeutic use (2817) 2817
adult (2634) 2634
drug therapy, combination (2527) 2527
clopidogrel (2526) 2526
ticlopidine - therapeutic use (2493) 2493
time factors (2486) 2486
peripheral vascular disease (2369) 2369
aspirin - adverse effects (2216) 2216
blood platelets (2160) 2160
ticlopidine - adverse effects (2134) 2134
hematology (2054) 2054
platelet aggregation - drug effects (1976) 1976
hemorrhage - chemically induced (1971) 1971
stents (1971) 1971
aged, 80 and over (1929) 1929
pharmacology & pharmacy (1884) 1884
aspirin - administration & dosage (1820) 1820
thrombosis (1786) 1786
anticoagulants - therapeutic use (1745) 1745
prospective studies (1708) 1708
anticoagulants - adverse effects (1689) 1689
general & internal medicine (1684) 1684
platelet aggregation inhibitors - pharmacology (1672) 1672
risk assessment (1630) 1630
animals (1615) 1615
retrospective studies (1602) 1602
care and treatment (1578) 1578
drug therapy (1578) 1578
heart attacks (1556) 1556
ticlopidine - administration & dosage (1536) 1536
medicine, general & internal (1506) 1506
blood platelets - drug effects (1497) 1497
cardiology (1448) 1448
platelets (1426) 1426
surgery (1413) 1413
cardiovascular (1375) 1375
stroke (1316) 1316
anticoagulants (1297) 1297
cardiovascular disease (1273) 1273
medicine & public health (1233) 1233
coronary heart disease (1220) 1220
cardiac patients (1206) 1206
analysis (1193) 1193
mortality (1177) 1177
percutaneous coronary intervention (1147) 1147
follow-up studies (1139) 1139
cardiovascular diseases (1110) 1110
acute coronary syndromes (1108) 1108
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (1106) 1106
thrombosis - prevention & control (1074) 1074
angioplasty, balloon, coronary - adverse effects (1053) 1053
randomized controlled trials as topic (1010) 1010
research (1006) 1006
angioplasty, balloon, coronary (979) 979
patients (977) 977
thrombosis - etiology (969) 969
dose-response relationship, drug (961) 961
health aspects (953) 953
acute coronary syndrome - drug therapy (949) 949
platelet aggregation (919) 919
blood platelets - metabolism (912) 912
stroke - prevention & control (906) 906
fibrinolytic agents - therapeutic use (899) 899
bleeding (870) 870
neurosciences & neurology (860) 860
dosage and administration (859) 859
myocardial infarction (858) 858
double-blind method (847) 847
myocardial infarction - drug therapy (846) 846
anticoagulants - administration & dosage (841) 841
drug administration schedule (841) 841
platelet function tests (831) 831
myocardial infarction - therapy (829) 829
drug-eluting stents (814) 814
coronary angiography (795) 795
stent (789) 789
coronary vessels (787) 787
clinical trials (783) 783
internal medicine (781) 781
drug interactions (770) 770
percutaneous coronary intervention - adverse effects (766) 766
aggregation (765) 765
transluminal angioplasty (764) 764
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17610) 17610
German (349) 349
Spanish (200) 200
French (190) 190
Japanese (172) 172
Italian (77) 77
Russian (71) 71
Portuguese (45) 45
Chinese (36) 36
Polish (36) 36
Danish (30) 30
Dutch (30) 30
Swedish (21) 21
Norwegian (18) 18
Czech (16) 16
Turkish (15) 15
Hungarian (11) 11
Korean (7) 7
Finnish (6) 6
Hebrew (6) 6
Serbian (4) 4
Croatian (3) 3
Lithuanian (3) 3
Bosnian (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2016, Volume 375, Issue 25, pp. 2423 - 2434
... – 3 Dual antiplatelet therapy (DAPT) with a P2Y 12 inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent, 4... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Confidence Intervals | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Kaplan-Meier Estimate | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Prevention | Complications and side effects | Angiography | Atrial fibrillation | Hemorrhage | Patients | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Angioplasty | Coagulation | Thrombosis | Thrombolysis | Bleeding | Fibrillation | Implants | Vitamin K | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
...‐mg/day maintenance dose) and the proton‐pump inhibitor (PPI) omeprazole (80 mg) when they are administered simultaneously (study 1... 
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
... of proton pump inhibitors and thienopyridines: a focused update of the ACCF ACG AHA 2008 expert consensus document on reducing the gastrointestinal risks... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Ryden, Lars and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and MERALI, FATIMA and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with carotid artery disease or with peripheral artery disease of the lower extremities are at high risk for major adverse cardiovascular events,1-3 and patients with peripheral artery disease... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article